CLAIM #54617 · SPG (SPG) · 2024Q4 earnings call · Feb 4, 2025 · due Dec 31, 2025
“we would expect to see or if we continue to see dollar strength, can see some impact over the course of the year, certainly in our translations of our foreign earnings.”
Brian McDade · CFO
In context
“ittle bit between sort of the outlets and the mall business, any sort of call out what drove the performance? Is it traffic? Is it higher ticket prices so on and so forth? And the second part of the question is really, are you seeing any impact from the strong dollar on tourist centers? Thanks. Brian McDade: So, Ron, it's Brian. There wasn't a big bifurcation kind of between asset classes. I think all three platforms performed exceedingly well. You did see the outlet in the mills, which generally skew a little bit more value oriented to outperform a little bit into the fourth quarter. It wasn't really kind of an anomaly just kind of expected performance. I mean, we've not seen any real time impact yet to the tourist oriented centers, but we're February 4th. So still early in the year, but we would expect to see or if we continue to see dollar strength, can see some impact over the course of the year, certainly in our translations of our foreign earnings. Ronald Kamdem: Thanks so much. David Simon: And I would just say when we talk about reenergizing on the assets. Don't just think malls, think outlets, think a few of our mills. So it's a wide portfolio focus, not just when people talk B, they always think malls, but for us it's across our entire domestic portfolio. Ronald Kamdem: Helpful. Thank you. David Simon: Thank you. Operator: This concludes the question-and-answer session. I'd like to turn the floor back to David Simon for any closing comments. David Simon: Okay. Thank you, everybody and look forward to talking in the future. Thank you. Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you again for your participation.”
Verify independently
SEC filings for SPG ↗ · Claim quote is verbatim from the 2024Q4 earnings call.